Also known as: BMS
Bristol Myers Squibb is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. It is publicly traded on the NYSE under BMY and develops major medicines including Eliquis, Opdivo, and Revlimid.
FDA approved iberdomide (Zenbexus) with daratumumab and dexamethasone for pretreated myeloma. The EXCALIBER-RRMM trial showed a 41% MRD-negative complete response rate vs 21%.
China has become the dominant source of external drug innovation, with pharma licensing deals reaching $135.7 billion in 2025 and China developing 30% of the world's new innovative drugs. Meanwhile, India is expanding AI use in drug discovery and strengthening its CRDMO and IP infrastructure, though investment gaps persist.
Blockbuster drugs worth hundreds of billions face generic competition as patents expire through 2032. Indian drugmakers could capture $3-5 billion of the opportunity, while GSK and Bristol Myers Squibb prepare for revenue losses.
Multiple myeloma immunotherapies like bispecific antibodies and CAR-T cells show high response rates and prolonged survival, but access is hindered by the need for initial hospital stays for bispecifics. Research indicates mezigdomide can reverse T cell exhaustion to boost these therapies, while longer-term CARVYKTI data show significant survival benefits.
Lawmakers opened national security probes into Merck, AbbVie and others over China drug trials. A survey finds China closing in on U.S. biotech leadership, and HHS launched clinical trial reforms to counter the rise.
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
Bristol Myers Squibb, Sanofi, and Pfizer have filed new patent infringement suits over drugs including Camzyos, Lantus, and abrocitinib, while the Federal Circuit denied Sarepta's rehearing bid in a Regenxbio DNA patent case.
Anthropic launched Claude Science, an AI workbench with 60+ skills and databases, and began preclinical programs for neglected diseases. A demo analyzed 100 rare genetic diseases in under an hour.
The FDA accepted Bristol Myers Squibb’s NDAs for iberdomide and mezigdomide, two CELMoD agents for relapsed/refractory multiple myeloma. Iberdomide has Priority Review and a PDUFA date of Aug. 17, 2026; mezigdomide’s is May 13, 2027. The filings are backed by Phase 3 data, including a 52% PFS risk reduction for mezigdomide.
ASCO 2026 data show CBM588 boosts immunotherapy in kidney cancer and a bispecific combo improves lymphoma. Early-day ICI infusion, mezigdomide T cell reinvigoration, and dostarlimab maintenance also advance cancer immunotherapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780383 |
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration |
NOT_YET_RECRUITING | PHASE1 |
| NCT07777133 |
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07777120 |
Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma |
ACTIVE_NOT_RECRUITING | |
| NCT07772531 |
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder |
NOT_YET_RECRUITING | PHASE2 |
| NCT07763418 |
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function |
NOT_YET_RECRUITING | PHASE1 |
| NCT07755826 |
Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan |
RECRUITING | |
| NCT07752121 |
First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms |
NOT_YET_RECRUITING | |
| NCT07732907 |
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia |
RECRUITING | |
| NCT07727668 |
Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07725497 |
A Study of Luspatercept in People With Anemia |
RECRUITING | PHASE2 |
